Dimerix Quarterly Activities Report and Appendix 4C
Filed with ASX ·
6ix is reading this filing.
Story so far
Earlier from Dimerix
- New Data Supports Biological Rationale for DMX-200 in FSGS
- DMX-200 First 100 Patients Complete Phase 3 Trial Treatment
- First Patient Reaches Four Years in DMX-200 Clinical Program
- Dimerix Draws Down A$17M Under Non-Dilutive Funding Facility
- Dimerix DMX-652 Granted Mexican Composition of Matter Patent
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix